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The NS2 protein generated by the parvovirus minute virus of mice is very labile, having a half-life during infection of
approximately 90 min. The degradation of NS2 is blocked by proteasome inhibitors but is likely ubiquitin independent: NS2
does not form detectable higher molecular weight ubiquitin-containing conjugates, and NS2 degradation requires neither
ubiquitin chain elongation nor intracellular ubiquitin activation. We have also identified a region in the carboxyl half of NS2
that is required for its proteasome-mediated degradation. © 2001 Academic Press
n
h
a
t
p
p
(INTRODUCTION
The autonomous parvoviruses encode two nonstruc-
tural proteins, NS1 and NS2, which play critical roles in
the viral life cycle (Vanacker and Rommelaere, 1995).
Because the mRNAs that encode these proteins are both
generated from the same pre-mRNA molecule, the rela-
tive abundances of NS1 and NS2 are controlled posttran-
scriptionally, at the level of alternative splicing and pro-
tein stability (Cotmore and Tattersall, 1990; Schoborg and
Pintel, 1991; Pintel et al., 1995). NS1 is a very stable
3-kDa nuclear phosphoprotein (with a half-life of over
h in infected cells), encoded by the singly spliced R1
RNA, that has multiple critical roles during viral repli-
ation (Vanacker and Rommelaere, 1995; Cotmore and
attersall, 1995). NS2, encoded by the doubly spliced R2
RNA, is a 25-kDa phosphoprotein that is present both
n the nucleus and in the cytoplasm of infected cells; the
hosphorylated forms are found only in the cytoplasm
Clemens et al., 1990; Cotmore and Tattersall, 1990). NS2
is very labile, yet it accumulates to high levels and is
required for productive minute virus of mice (MVM) in-
fection in a host-range-dependent manner (Naeger et al.,
1990, 1993; Cotmore and Tattersall, 1990; Li and Rhode,
1991; Cotmore et al., 1997). The role that NS2 plays
uring infection is not yet clear. NS2-null mutants show a
triking defect in the accumulation of all virus replicative
orms in restrictive cells, and NS2 mutants have been
hown to exhibit defects in capsid assembly (Naeger et
l., 1990, 1993; Li and Rhode, 1991; Cotmore et al., 1997).
S2 is known to bind to three cellular proteins, the
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346uclear export factor Crm1 (Bodendorf et al., 1999; Ohs-
hima et al., 1999) and two of the 14-3-3 family of multi-
functional signaling adaptor proteins, e and b or z (Brock-
aus et al., 1996). The consequence of these interactions
re not yet clear.
The degradation of most cellular and many viral pro-
eins is carried out by the 26S proteasome, a cellular
rotease made up of two distinct multisubunit com-
lexes, the 20S catalytic core and the 19S regulatory cap
see DeMartino and Slaughter, 1999; Zwickl et al., 1999
for review). Although the 20S core proteasome can be
made active in vitro upon mild denaturation, its activity in
vivo is thought to require association with the 19S cap
complex (DeMartino and Slaughter, 1999). Protein deg-
radation is usually mediated by direct conjugation of
multi-ubiquitin chains to degradation substrates, which
are then recognized by the 19S regulatory cap, unfolded,
and fed into the inner chambers of the 20S core protea-
some in an ATP-dependent manner (Hershko and Ciec-
hanover, 1998; Zwickl et al., 1999). There are only a few
reported exceptions to this mode of degradation. Orni-
thine decarboxylase, through interaction with the inhibi-
tor protein antizyme, is directed to the 26S proteasome
where it is inactivated, sequestered, and then degraded
by the proteasome in an ATP-dependent and ubiquitin-
independent manner (Murakami et al., 1992, 1999). The
cyclin-dependent kinase, p21, although a substrate for
ubiquitination, was also recently shown to be degraded
by the proteasome in a ubiquitin-independent manner
(Sheaff et al., 2000).
It seems likely that the instability of NS2 is important
for its function during virus infection. In this report we
show that the degradation of MVM NS2 is performed by
the proteasome; however, it is highly likely that NS2
degradation is independent of ubiquitin conjugation. In
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347MVM NS2 DEGRADATIONaddition, we have identified a region in NS2 that is
involved in its proteasome-mediated degradation.
RESULTS
Degradation of NS2 is dependent upon the
proteasome
During wild-type viral infection, NS2 is quite labile.
Pulse–chase experiments suggested that its half-life, in
infected murine A9 cells, was approximately 90 min (Fig.
1). The degradation of NS2 was dramatically blocked by
well-characterized inhibitors of the 20S proteasome. Ad-
dition to infected cells of MG132 [a proteasome sub-
strate analog which competitively inhibits both the chy-
motrypsin-like and the peptidylglutamyl-peptide-hydro-
lyzing (PGPH) activity of the 20S proteasome in addition
to other cellular proteases (Rock et al., 1994)], lactacystin
[which specifically inhibits the chymotrypsin-like, trypsin-
like, and PGPH activity of the 20S proteasome by irre-
versibly modifying all catalytic subunits (Fenteany et al.,
1995)], or epoxomicin [which strongly and very specifi-
cally inhibits the chymotrypsin-like and, to a lesser ex-
tent, the trypsin-like and PGPH activity of the 20S pro-
teasome by specifically and irreversibly binding co-
valently to the LMP7, MECL, X, and Z catalytic subunits
(Meng et al., 1999)] increased the half-life of NS2 signif-
icantly. At 90 min, when approximately half of the un-
treated NS2 samples had degraded, levels of the inhib-
itor-treated samples remained essentially unchanged.
Extrapolation of the degradation curves in Fig. 1 showed
that MG132, lactacystin, and epoxomicin increased the
half-life of NS2 by approximately eightfold, by approxi-
mately sixfold, and to almost complete stability for the
duration of the assay (180 min), respectively (Fig. 1).
These results indicated that the 20S proteasome medi-
ates NS2 degradation. NS2 generated from transfected
plasmids exhibits a lability and sensitivity to proteasome
inhibitors similar to that of NS2 generated during infec-
tion.
NS2 does not form detectable higher molecular
weight ubiquitin-containing conjugates in the
presence of a proteasome inhibitor
The great majority of proteins that are degraded by the
26S proteasome are targeted for degradation by ubiq-
uitin conjugation (Hershko and Ciechanover, 1998;
Zwickl et al., 1999). Such conjugates are typically detect-
able in the presence of proteasome inhibitors (Clurman
et al., 1996). We therefore investigated whether NS2
formed ubiquitin conjugates in the presence of MG132.
Cyclin E, known to be degraded by the 26S proteasome
in a ubiquitin-directed manner, served as a positive con-
trol. Following cotransfection of A9 cells with both a
HA-tagged ubiquitin and a myc-tagged cyclin E-express-
ing plasmid, and the subsequent addition of MG132,HA–ubiquitin-containing, higher molecular weight conju-
gates of specifically immunoprecipitated cyclin E could
be readily demonstrated by Western analysis using a-HA
antibody (Fig. 2, bottom left). a-HA antibody also specif-
cally immunoprecipitated material subsequently recog-
ized on Western by a-c-myc antibody (Fig. 2, bottom
FIG. 1. Degradation of NS2 in the presence of proteasome inhibitors.
Pulse–chase experiments were performed, using a-NS1/2 N-terminal
ntibody, either in the absence or in the presence of proteasome
nhibitor lactacystin (5 mM), MG132 (10 mM), or epoxomicin (10 mM),
utilizing chase periods of 0, 30, 90, or 180 min following MVM infection
of A9 cells, as shown. Representative experiments are shown at the
center and bottom and NS1 and NS2 are designated. A graph showing
the average of three experiments as measured by phosphorimager
analysis in the absence (—, ) and presence of lactacystin (– z –, n ),
MG132 (– – –, E), and epoxomicin (- - -, }) is shown at the top. Best fit
linear regression lines are shown and indicate a half-life for NS2 of
approximately 90 min. Relative phosphoimager units of NS2 were
standardized to relative units of stable NS1 within each sample to
control for loading errors.center). Similar experiments clearly demonstrate ubiq-
uitin conjugation to p21 (data not shown). In contrast,
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348 MILLER AND PINTELunder similar experimental protocols done in parallel,
such higher molecular weight, HA–ubiquitin-containing
conjugates of NS2 were not detected (Fig. 2, top left and
center), although NS2 was expressed at high levels (Fig.
2, top right) and was readily precipitated with the same
a-NS2 antibody from labeled cells transfected in parallel
(data not shown). Similar experiments also repeatedly
failed to detect NS2 conjugates with endogenous ubiq-
uitin in infected or transfected cells (data not shown). In
addition, the conjugation of ubiquitin to NS2 could not be
detected by pull-down assays using either labeled GST–
ubiquitin mixed with cold in vitro-generated NS2 or cold
ST–ubiquitin mixed with labeled in vitro-generated NS2
data not shown). These results, although negative in
ature, suggested that perhaps degradation of NS2 by
he 20S proteasome did not require ubiquitination of
S2. We therefore chose to further examine NS2 degra-
ation following disruption of ubiquitin chain elongation
FIG. 2. There are no detectable higher molecular weight ubiquitin-co
92L cells were transfected with pCMVNS2 (top) or pCS2-MTcyclinE
G132 was added to cells 6 h posttransfection where indicated. 18 h
ith either a-NS2 (top left) or a-c-myc (to precipitate myc-tagged cyclin
ith a-HA antibody, immunoprecipitated with a-HA antibody followed
middle) antibody, or loaded directly on SDS–PAGE without immunoprec
bottom right) antibody. The identity of the band marked by an asterisk
orms of cyclin E are identified. Cross-reactive IgG heavy and light cha
el shown in the upper left.nd ubiquitin activation, two critical steps required for
biquitin-dependent degradation, as has been done pre-viously to establish that the degradation of p21 was
ubiquitin independent.
NS2 degradation does not require ubiquitin chain
elongation
Processive ubiquitin chain elongation, a required step
for recognition of ubiquitin-mediated degradation sub-
strates by the regulatory subunit of the 26S proteasome,
can be blocked by the lysine-less dominant-negative
form of ubiquitin, UbR7, and transfection of a UbR7-
expressing plasmid blocks the degradation of proteins
that are targeted to the proteasome by ubiquitin (Sheaff
et al., 2000). While transfection of a UbR7-expressing
plasmid clearly blocked the degradation of cotransfected
cyclin E (Fig. 3, top), it had no significant effect on the
lability of cotransfected NS2 (Fig. 3, center). The stability
of p21, a protein known to be ubiquitinated, but whose
g NS2 conjugates in the presence of the proteasome inhibitor MG132.
). pHAUb was cotransfected with the test plasmids where indicated.
nsfection cells were split into three samples and immunoprecipitated
ttom left) and loaded on SDS–PAGE followed by Western blot analysis
tern blot analysis with either a-NS2 (top middle) or a-c-myc (bottom
n followed by Western blot analysis with a-NS2 (top right) or a-c-myc
own. NS2, cyclin E, and higher molecular weight ubiquitin-containing
also identified; however, these are underrepresented in the particularntainin
(bottom
posttra
E, bo
by Wes
ipitatio
is unkndegradation does not require ubiquitination (Sheaff et al.,
2000), was similarly unaffected by the dominant-negative
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349MVM NS2 DEGRADATIONFIG. 3. NS2 degrades normally in the absence of ubiquitin chain elongation. A92L cells were transfected with pCS2-MTcyclinE (top), pCMVNS2
middle), or pCS2p21 (bottom) either alone or cotransfected with pUbR7. 18 h posttransfection, cells were pulse labeled with 35S and then chased for
, 30, 90, and 180 min. Immunoprecipitations were done with a-c-myc to detect cyclin E (top), a-NS2 (middle), or a-p21 (bottom) antibodies. A
epresentative set of experiments is shown on the right. Graphs depicting the log % degradation of cyclin E in the absence (- - -, ) and presence
—, }) of UbR7 (top left), NS2 in the absence (– – –, h) and presence (—, n ) of UbR7 (middle left), and p21 in the absence (—, E) and presence
– z –, F) of UbR7 (bottom left) are shown and represent the average of three separate experiments as measured by phosphorimager analysis.
he best fit linear regression line is shown for each. The positions of NS2, p21, and cyclin E (cycE) are shown.
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350 MILLER AND PINTELmutant of ubiquitin (Fig. 3, bottom). These results are
consistent with the model that NS2 degradation does not
require prior multiubiquitination.
The accumulation of NS2 is not affected by the
absence of intracellular ubiquitin activation
The activation of ubiquitin, which is catalyzed in an
ATP-dependent reaction by the cellular E1 enzyme, is a
necessary step in ubiquitin-dependent degradation (Her-
shko and Ciechanover, 1998). In mammalian cells there
is a single E1 protein, and thermal inactivation of tem-
perature-sensitive mutants of this protein results in the
stabilization of protein targets that require ubiquitination
for degradation (Cox et al., 1995). The murine L cell-
erived tsA1S9 and other cell lines (Cox et al., 1995;
Clurman et al., 1996) which contain a mutation in the E1
gene rendering its product inactive at 40°C have been
used to implicate ubiquitination in the degradation pro-
cess of certain cellular proteins, like cyclin E (Clurman et
al., 1996), in the following manner. Following transfection
and expression at the permissive temperature of 32°C, at
which the E1 protein is active, the ubiquitin-dependent
cyclin E protein accumulated to a much greater degree in
the presence of the proteasome inhibitor MG132 than it
did in its absence (Fig. 4, left). At 40°C, however, at which
E1 was thermally inactivated and hence ubiquitin was
not activated, there was little difference in the accumu-
lation of cyclin E in the presence vs the absence of
inhibitor (Fig. 4, left). In parallel experiments, however,
the ratio of the accumulation of NS2 in the presence vs
FIG. 4. The accumulation of NS2 is not affected by the absenc
pCST-MTcyclinE or pCMVNS2 at the permissive temperature of 32°C. S
temperature of 40°C and MG132 (10 mM) was added. 18 h posttrans
DS–PAGE. Western blot analysis was performed using either a-c-
chemiluminescence screen and phosphorimager units were determine
are the average protein accumulations measured in the absence and p
E1, respectively), from two experiments. The positions of NS2 and cycthe absence of inhibitor following transfection of tsA1S9
cells was found to be similar at temperatures permissive,and restrictive, for E1 activity (Fig. 4, right). These results
further suggested that degradation of NS2 is not a ubiq-
uitin-mediated process.
Although we have determined by pulse–chase exper-
iments that the half-life of NS2 is increased in the pres-
ence of MG132, we also observed, for reasons as yet
unclear, a general decrease in the overall accumulated
levels of NS2 in the presence of proteasome inhibitors.
This observation, together with the fact that cyclin E is
three- to fourfold more labile than NS2 (Fig. 3, top), can
explain why cyclin E is seen to accumulate to a greater
extent during the 12-h inhibitor treatment at the permis-
sive temperature than does NS2 (Fig. 4).
Mapping the region of NS2 that governs degradation
The cis-acting signals that target proteins for degra-
dation via the ubiquitin cascade have been extensively
studied (Hershko and Ciechanover, 1998); however, little
is known about the cis-acting signals that might target
proteins for degradation in a ubiquitin-independent man-
ner. We next, therefore, attempted to identify a region, or
regions, of NS2 that might govern its lability. We found
that for NS2, this signal is complex.
Because NS1 and NS2 share 84 amino acids at their
amino terminus, and NS1 is a very stable protein, we
suspected that if NS2 had a signal that governed its
lability, at least a part of this signal might be in the
carboxyl half of the molecule. To investigate this region
further, we initially examined NS2 molecules generated
by a mutant, which has been previously described (Nae-
tracellular ubiquitin activation. TsA1S9 cells were transfected with
s posttransfection, where indicated, cells were shifted to the restrictive
cells were collected and equivalent amounts of protein were run on
detect cyclin E or a-NS2 as indicated. Blots were exposed to a
presentative experiment is shown, and the ratios given at the bottom
of MG132, at both 32 and 40°C (permissive and restrictive for cellular
ycE) are shown.e of in
ix hour
fection
myc to
d. A reger et al., 1990), in which a translation termination signal
was introduced into the infectious clone of MVM imme-
error. A
s for ea
351MVM NS2 DEGRADATIONdiately upstream of the small intron at nt 2268. The NS2
molecules produced by this mutant had a lability indis-
tinguishable from that of wild type (data not shown),
indicating that amino acid heterogeneity at the very car-
boxyl terminus of NS2 was likely not involved in NS2
degradation and suggesting further that the labilities of
all the individual isoforms of NS2 were regulated simi-
larly.
We next examined a series of frame-shift mutations
FIG. 5. The NS2 C-terminus is required for its proteasome-mediated
in graphical form. S, stable; L, labile; R, random sequence; * indicates m
(B) Representative experiment showing the degradation of NS2 generat
with NS2 wild-type and mutant expression plasmids as indicated. 18 h
for 0, 30, 90, and 180 min. Immunoprecipitation was performed using a
of five, seven, and nine experiments with CMVFS2125, CMVFS2175, an
counts were equilibrated to NS1 counts to control for sample loading
the presence of 10 mM epoxomicin. The best fit linear regression linebetween ORF 2 and ORF 3 which replaced residues of
NS2 with those of NS1 at various positions (Fig. 5). Whenthe NS2 reading frame was shifted such that NS1 se-
quences replaced NS2 sequences downstream of nt
2011 (CMVFS2011, Fig. 5A), nt 2072 (CMVFS2072, Fig.
5A), or nt 2125 (CMVFS2125, Figs. 5A–5C), the resulting
molecule was stabilized .10-fold, suggesting that a re-
gion required for lability lay between nt 2125 and nt
2268. When a frame shift was introduced at nt 2175, so
that NS2 sequences were retained until this point
(CMVFS2175), the resultant molecule regained insta-
dation. (A) The mutations described and their relative labilities shown
that were more stable than wild-type NS2 but not as stable as FS2125.
MVFS2125, CMVFS2175, and CMVNS1/2. A92L cells were transfected
ansfection, cells were pulse labeled for 1 h with 35S and then chased
1/2 N-terminal antibody. NS1 and NS2 are indicated. (C) The averages
NS1/2, respectively, as determined by phosphorimager analysis. NS2
lso shown in C is the degradation of pCMVFS2175-generated NS2 in
ch are plotted.degra
utants
ed by C
posttr
n a-NS
d CMVbility of a magnitude at least as great as that of
wild-type NS2 (Figs. 5A–5C). The degradation of CM-
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352 MILLER AND PINTELVFS2175-generated NS2, like that of wild-type NS2,
was also clearly mediated by the proteasome: treat-
ment with epoxomicin stabilized this mutant protein
10-fold (Fig. 5C). Molecules in which a frame shift was
introduced at nt 2150 showed an intermediate pheno-
type (CMVFS2150, Fig. 5A). These results suggested
that aa 131–146 in the region of NS2 between nt 2125
and nt 2175 were involved in its degradation by the
proteasome; however, it remained possible that the
addition of the NS1 amino acids that correspond to
the nt 2125–2175 region conferred stability to the
CMVFS2125-generated NS2 chimera. Replacing the
NS1 sequence with random amino acid sequence be-
tween nt 2150 and nt 2175 in the CMVFS2175 frame-
shift mutant generated a molecule more stable than
wild-type (CMVSD812175, Fig. 5A); furthermore, when
amino acids 131–146 of otherwise wild-type NS2 were
replaced with NS1 amino acids, the resulting protein
was unstable. These results argued against the pos-
sibility that the NS1 residues provided a stabilizing
element (CMVFS21251FS2175, Fig. 5A). However,
hen we then replaced the residues between nt 2150
nd nt 2175 or nt 2125 and nt 2175 of the wild-type NS2
olecule with a random sequence to determine if this
egion was sufficient for NS2 lability (CMVSD8 and
MVSD16, respectively), the resultant molecule re-
ained labile (Fig. 5A), suggesting that although
mino acids 131–146 are involved in the proteasome-
ediated degradation of NS2, this region is not the
ole determinant of NS2 lability.
DISCUSSION
The degradation of NS2 is highly sensitive to three
roteasome inhibitors of different specificity; however,
e were unable to detect conjugation of ubiquitin to NS2
n any of the assays that we performed, either in vivo or
n vitro, although ubiquitin conjugation to both cyclin E
nd p21 was clearly demonstratable in our assays.
hese results, although negative, suggested that ubiq-
itin conjugation to NS2 may not be necessary for its
egradation. As done to establish another example of
biquitin-independent degradation (Sheaff et al., 2000),
e further examined NS2 degradation following the dis-
uption of two critical steps required for ubiquitin-depen-
ent degradation, ubiquitin chain elongation and ubiq-
itin activation. Blocking ubiquitin chain elongation using
he dominant-negative UbR7 form of ubiquitin efficiently
locked cyclin E degradation, but had little effect on the
alf-life of NS2 (or p21). Inhibiting the ubiquitin-depen-
ent degradation pathway even earlier, by blocking the
ctivation of ubiquitin in E1 temperature-sensitive cell
ines, again altered the stability of the ubiquitin-depen-
ent cyclin E, but had little to no effect on the stability of
S2. Taken together, these results led us to concludehat NS2 degradation, although proteasome dependent,
s highly likely to be independent of ubiquitination.
The mechanism of degradation of proteins that are
egraded by the 26S proteasome in a ubiquitination-
ndependent manner is not well understood. Ornithine
ecarboxylase, the best understood ubiquitin-indepen-
ent degradation substrate, must interact with the inhib-
tor protein antizyme to be degraded by the 26S protea-
ome (Murakami et al., 1992), and it has been proposed
hat this interaction may induce a conformational change
nd expose a C-terminal degradation signal of ODC,
hich is then targeted to the interior of the proteasome
Murakami et al., 1999). Although NS2 has been shown to
nteract with three cellular proteins [Crm1 (Bodendorf et
l., 1999; Ohshima et al., 1999) and two 14-3-3 family
embers, e and b or z (Brockhaus et al., 1996)], and the
egion of NS2 that interacts with the 14-3-3 proteins (N.
alome, personal communication) is just downstream of
region of NS2 involved in its lability, there is no evi-
ence yet that these proteins play a role in NS2 degra-
ation. When the interactions between NS2 and these
roteins were disrupted by mutation, degradation of NS2,
s measured by pulse–chase assay of bulk NS2, was
elatively unaffected (C. L. Miller and D. J. Pintel, unpub-
ished).
Viral infection can lead to apoptosis of infected cells,
nd the NS1 protein of parvoviruses has been shown to
nduce apoptosis in cells when ectopically expressed
Moffatt et al., 1998). This raised the possibility that NS2
egradation may have been mediated by activation of
he cellular proteases that are responsible for the bulk of
poptotic protein cleavage. Treatment of CMVNS1/2-
ransfected cells transfected with the general caspase
ubstrate inhibitor z-vad-FMK (Luo et al., 1998), however,
did not result in the stabilization of NS2. It also seems
unlikely that NS2 is first cleaved by other cellular pro-
teases and then degraded by the proteasome, because
proteasome inhibition resulted in the stabilization of full-
size NS2 molecules (as determined by SDS–PAGE, see
Fig. 1). It is conceivable that NS2 is recognized and binds
directly to the 26S proteasome where it is then degraded.
Although there have been reports of the proteasome
being capable of degrading unfolded substrates in vivo
(DeMartino and Slaughter, 1999), there is little reason to
believe that NS2 is present in an unstructured form
during MVM infection. The selective degradation of pro-
teins is often part of a regulatory mechanism involving
timing control; however, NS2 accumulates to high levels
throughout MVM infection (Cotmore and Tattersall, 1990;
Schoborg and Pintel, 1991). It is intriguing that NS2 would
be made at such high levels only to be then degraded
very quickly. This would be compatible with a function of
NS2 resulting in its degradation, such that new protein is
always needed.There has been considerable attention given to the
identification of cis-acting sequences that target proteins
t
N
b
a
t
r
r
p
r
t
m
s
w
s
w
N
c
t
C
d
c
a
a
A
p
m
r
d
h
(
c
M
c
8
s
f
p
f
353MVM NS2 DEGRADATIONfor ubiquitination (Hershko and Ciechanover, 1998). Very
little is known, however, about the regions that may
target proteins for degradation in a ubiquitin-indepen-
dent manner. Our attempts to identify a region of NS2
that governs its instability were only partially successful.
Replacement of NS2 sequences with those of NS1 sug-
gested that residues between nt 2125 and nt 2175 were
important for the proteasome-mediated degradation of
NS2; however, these residues were not the only region of
NS2 that could lead to its destruction because replacing
them with random sequence did not result in a stable
NS2 molecule. In fact, any mutant in which the region
between either 2125 and 2175 or 2175 and 2268 con-
ained wild-type NS2 sequences generated an unstable
S2 protein. Those mutants in which both the regions
etween 2125 and 2175 and 2175 and 2268 were either
ltered or changed completely generated an NS2 protein
hat was more stable than wild type. Whether these
egions participate in affecting the stability of NS2 di-
ectly or have other effects (i.e., on localization or phos-
horylation) that might affect the stability of NS2 indi-
ectly is not known. These results do suggest, however,
hat NS2 contains at least two distinct cis-acting ele-
ents involved in its degradation, either of which is
ufficient without the other. Further studies are under
ay to identify these elements more precisely. A frame-
hift mutation that replaced the carboxyl terminus of NS1
ith that of NS2 (CMVFSX27) was as stable as wild-type
S1, suggesting that these signals are not sufficient to
onfer lability either in general or, more specifically, to
he rather large and stable, nuclearly localized, NS1.
MATERIALS AND METHODS
ells, viruses, and transfections
Murine A92L cells were maintained and passaged as
escribed (Tattersall and Bratton, 1983). The murine L-
ell derivative tsA1S9 (Cox et al., 1995) was maintained
t 32°C. Wild-type and mutant MVMp virus was grown
nd titered on 324K cell monolayers and used to infect
92L cells at a multiplicity of 3. NS2-2268 has been
reviously described (Naeger et al., 1990). The MVM
utant which loses interaction with 14-3-3 proteins as a
esult of changing NS2 aa 149 from T to A was made as
escribed (N. Salome, personal communication; Brock-
aus et al., 1996). The NS2:Crm1 interaction mutation
which was made according to N. Salome, personal
ommunication, and Ohshima et al., 1999), changed
VM nt 1990–2008 such that the NS2 amino acids
hange from aa 84–FGTLJI–aa 89 to aa 84–VCPVAV–aa
9, without altering the NS1 amino acid sequence. Tran-
ient transfection assays were performed with Lipo-
ectamine and Plus reagent as recommended by sup-
lier (Gibco BRL, Grand Island, NY). Cells were trans-
ected with 2 mg plasmid DNA, when a single plasmidwas transfected, or 1 mg each plasmid DNA when co-
transfected.
Plasmid constructs
The pCMVNS1/2 plasmid was made by inserting MVM
sequences 225–4342 (missing nt 2652–3996) into the
MCS of pcDNA 3.1 (Invitrogen) such that both full-length
NS1 and NS2 are expressed. pCMVNS2 was constructed
by replacing the EcoRV–XhoI fragment of pCMVNS1/2
with the same fragment from the NS2 cDNA clone (Cle-
mens et al., 1990) so that only NS2 was expressed. The
CMVFS2125, CMVFS2150, and CMVFS2175 mutants
were constructed by overlap PCR mutagenesis (Haut
and Pintel, 1998), such that a single nucleotide was
removed at nt 2125, 2150, and 2175 respectively, shifting
the NS2 ORF 2 into the NS1 ORF 3 at that point. To
generate pCMVFS2011, nt 1248–4342 (minus 2652–3996)
of pfs2011 (Gersappe and Pintel, 1999), an MVM plasmid
that has a single nucleotide deletion at nt 2011, shifting
the NS2 ORF 2 into the NS1 ORF 3 at that point, was
inserted into pCMVNS1/2. To generate pCMVFS2072, nt
1248–4342 (minus 2652–3996) of Tb60 (Naeger et al.,
1992), a plasmid that has a single nucleotide deletion at
nt 2072, shifting the NS2 ORF 2 into the NS1 ORF 3 at
this point, was inserted into pCMVNS1/2. To generate
pCMVX27, nt 1248–4342 (minus 2652–3996) of X27
(Naeger et al., 1992), a plasmid that has a two-nucleotide
deletion at nt 2072, shifting the NS1 ORF 3 into the NS2
ORF 2 at that point, was inserted into pCMVNS1/2. pC-
MVSD8 was generated by overlap PCR mutagenesis
such that eight random amino acids replaced NS2 resi-
dues 131–139 of pCMVNS1/2, changing aa 139–SWFQS-
LPR–aa 146 to aa 139–GGVKGYAG–aa 146. pCMVSD16
was made by overlap PCR mutagenesis such that 16
random amino acids replaced NS2 residues 131–146
in pCMVNS1/2, changing NS2 from aa 131–CRNPEH-
WGSWFQSLPR–aa 146 to aa 131–GGDAQYRRGGVK-
GVAG–aa 146 without altering the NS1 protein.
pSD812175 was also made by overlap PCR mutagen-
esis such that eight random amino acids replaced
residues 139–146 in pCMV2175, changing aa 139–
SWFQSLPR–aa 146 to aa 139–GGVKGVAG–aa 146.
pCMVFS21251FS2175 was made by overlap PCR mu-
tagenesis such that a single nucleotide deletion was
introduced at both nt 2125 and nt 2175 of pCMVNS1/2,
shifting the NS2 ORF into the NS1 ORF at nt 2125, then
back into the NS2 ORF at nt 2175. pHAUb was con-
structed by inserting an oligonucleotide coding for the
HA tag YPYDVPDYA into pcDNA3.1 and then inserting
the ubiquitin gene from pYEP96 (Ecker et al., 1987) in
frame behind the HA tag. SP6NS2 was previously
described (Lorson et al., 1996). pGEX-2TK-Ubiquitin
was a gift from John Cannon, University of Missouri.
pCS2p21, myc-tagged pCS21MTcyclinE, and pUbR7
were gifts from B. Clurman (Sheaff et al., 2000).
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354 MILLER AND PINTELPulse–chase and immunoprecipitation assays
Cells were labeled with 100 mCi/ml 35S 18 h posttrans-
ection or 24 h postinfection and pulse–chase assay was
erformed as previously described (Schoborg and Pintel,
991) with the following changes. Proteasome inhibitors
G132 (10 mM), lactacystin (5 mM), and epoxomycin (10
mM) (Affiniti Research Products Limited, Exeter, UK) were
added to cells 3 h prior to labeling where indicated and
were present throughout the pulse and chase periods.
When labeling pCS2p21- or pCS2-MTcyclinE- transfected
cells, 35S exposure time was 30 min. When labeling
MVMp-infected or pCMVNS1/2 (and derivative plas-
mids)-transfected cells, 35S exposure time was 60 min.
Labeled cells were collected and immunoprecipitation
was performed as described (Clemens et al., 1990) with
the following changes. Cells were lysed in 2% SDS and
further denatured by 10-min incubation at 90°C. RIPA
buffer (Naeger et al., 1990) was added to final SDS
concentration of 0.25%. Five microliters from each sam-
ple was removed and counted by scintillation counter.
Equivalent counts from each sample were added to the
appropriate antibody for incubation. After immunopre-
cipitation, dried gels were exposed to a Kodak phospho-
imaging screen (Bio-Rad) and quantitated using a Bio-
Rad Imager FX and Quantity One software. Where appli-
cable, NS2 counts were equilibrated to NS1 counts to
control for sample loading differences. Antibodies used
include rabbit polyclonal a-NS2 C-terminal, made
gainst C-terminal NS2 peptide aa 156–182; rabbit poly-
lonal a-NS1/2 N-terminal, made against a peptide con-
aining aa 5–25 shared by both NS1 and NS2 proteins;
abbit polyclonal a-p21 (C19) (Santa Cruz Biotechnology,
nc., Santa Cruz, CA); and mouse monoclonal a-c-myc
Boehringer Mannheim).
sA1S9 assay
Assays were done as has been previously described
y Clurman et al. (1996). Six hours posttransfection of
sA1S9 cells at 32°C, MG132 (10 mM) was added to four
f eight transfected plates. Two plates containing
G132, and two plates without MG132, were then shifted
o the nonpermissive temperature of 40°C, while two
lates containing MG132, and two plates without MG132,
emained at the permissive temperature of 32°C. After a
2-h incubation, the cells were collected and lysed, and
otal protein levels were determined by Bradford assay.
quivalent amounts of protein were run on SDS–PAGE
nd transferred to nitrocellulose. Western blot analysis
as performed as described (Amersham, Inc.) and the
roteins were visualized by chemiluminescence (Pierce
uperSignal) on film. In parallel, blots were exposed to a
hemiluminescence screen (Bio-Rad) and quantitated
sing a Bio-Rad Imager FX and Quantity One software.mmunoprecipitation and Western analysis
MG132 (10 mM) was added to cells where indicated
h posttransfection. Cells were collected 18 h posttrans-
ection and lysed in nondenaturing Raf buffer (Bodendorf
t al., 1999) containing 13 protease inhibitors (Sigma).
ysates were added to 8 ml antibody and incubated,
otating at 4°C for 4 h. One hundred microliters of a 50:50
af buffer:protein A–Sepharose slurry was added, and
he samples were incubated for an additional hour. Sam-
les were washed three times with Raf buffer, resus-
ended in 13 IP dye, run on 10% SDS–PAGE, and trans-
ferred to nitrocellulose, and Western blot analysis was
performed as described (Amersham, Inc.). Blots were
visualized by chemiluminescence on film. Antibody not
previously mentioned was mouse monoclonal a-HA.11
(Covance, Richmond, CA).
In vitro GST pull-down assays
GST–ubiquitin was made, purified, and labeled with
32P as previously described (Mouw and Pintel, 1998).
35S-labeled, or unlabeled, TNT-generated NS2 was made
s previously described (Lorson et al., 1998). Beaded
abeled GST–ubiquitin and cold NS2, or cold beaded
ST–ubiquitin and labeled NS2, were incubated together
n an S100 cytoplasmic extract or reticulocyte lysate for
5 or 90 min, washed three times, and run on SDS–PAGE.
els were dried and exposed to film to visualize possible
nteractions.
-vad-FMK inhibitor assay
Eighteen hours posttransfection, A92L cells were
reated with caspase inhibitor z-vad-FMK (Enzyme Sys-
ems Products, Livermore, CA) at a final concentration of
0 mM, as indicated by the supplier. After a 2-h incuba-
ion, pulse–chase analysis and immunoprecipitation
ere performed as described above.
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